<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Antimicrobial resistance | Hunter Ratliff</title>
    <link>/tag/antimicrobial-resistance/</link>
      <atom:link href="/tag/antimicrobial-resistance/index.xml" rel="self" type="application/rss+xml" />
    <description>Antimicrobial resistance</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><copyright>© Hunter Ratliff 2026</copyright><lastBuildDate>Thu, 29 Oct 2026 08:00:00 +0000</lastBuildDate>
    <image>
      <url>/images/icon_hu8e426841df379e4eaaa7ef046859ab6f_13357_512x512_fill_lanczos_center_2.png</url>
      <title>Antimicrobial resistance</title>
      <link>/tag/antimicrobial-resistance/</link>
    </image>
    
    <item>
      <title>Choose your own antibiotics</title>
      <link>/talk/cid-2026-10-29/</link>
      <pubDate>Thu, 29 Oct 2026 08:00:00 +0000</pubDate>
      <guid>/talk/cid-2026-10-29/</guid>
      <description>&lt;div class=&#34;alert alert-note&#34;&gt;
  &lt;div&gt;
    Click on the &lt;strong&gt;Slides&lt;/strong&gt; button above for the powerpoint slides (&lt;strong&gt;PDF&lt;/strong&gt; version available). Citations (with PubMed links) are under the &lt;strong&gt;Citations&lt;/strong&gt; button
  &lt;/div&gt;
&lt;/div&gt;
&lt;h2 id=&#34;ai-generated-summary&#34;&gt;AI Generated Summary&lt;/h2&gt;
&lt;p&gt;This joint ID and pulmonary/critical care conference follows a single patient through a prolonged hospitalization after a biliary leak that was never fully source controlled. Over roughly four months he had recurrent VRE and Burkholderia cepacia complex bacteremias, candidemia, repeated pneumonias and intra-abdominal flares, and serial airway cultures that grew multidrug-resistant &lt;em&gt;Pseudomonas aeruginosa&lt;/em&gt; with shifting susceptibility patterns, despite more than nine weeks of cefiderocol.&lt;/p&gt;
&lt;p&gt;The discussion uses his isolates to challenge the model implied by the lab report: that a culture is one clonal population, that S means the drug kills all of it, and that the S drug cures the patient. It covers why large populations carry resistant subpopulations and what resistance costs the bacterium, how heteroresistance, mixed strains and evolution within the patient look identical on a routine panel, and how an antibiogram is built from the colonies the lab happens to pick. A cefiderocol section reviews heteroresistance, the difficulty of susceptibility testing, cross-resistance with ceftolozane-tazobactam and ceftazidime-avibactam, and CREDIBLE-CR, with MERINO and inducible AmpC as familiar examples of an S that can fail.&lt;/p&gt;
&lt;p&gt;The talk closes with the 90-60 rule: about 90% of infections with susceptible isolates respond, and about 60% with resistant isolates still do. Source control, host, site and dose often matter more than the panel, and after long exposure a susceptible result is best treated as a soft S.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
